Xxxx Xxxxxxxx X. X. Xxxxxxxx, Xxxxxxx-000000, hereinafter referred to and called the “OWNERS/VENDORS /FIRST PART NO. 1.” (which expression shall unless excluded by or repugnant to the context hereof be deemed to include their respective heirs executors, legal representatives, administrator: and/or assigns) of the FIRST PART duly represented by (1)
Xxxx Xxxxxxxx X. Xxxxx Xxxx; Xxxxxx, Xxxxx; Xxxxxx, Xxxxx; Xxxxxx, Xxxx Agreement re WPX West Alamito Unit-Encana Proposed Expansion of North Alamito Unit I have confirmed with Encana your description of the agreement on the course forward. Thanks Xxx.
Xxxx Xxxxxxxx X. X., x xxxxxxx xncorporated in the Republic of Liberxx xith its registered office at 80 Broad Street, Monrovia, Liberia (the "Current Owner"); and
Xxxx Xxxxxxxx X. Xxxxxx with a copy to: Stoel Rives LLP One Union Square 000 Xxxxxxxxxx Xxxxxx Xxxxx 0000 Xxxxxxx, XX 00000-0000 Attention: Xxxxxx X. Lone or to such other address or to the attention of such other person as the recipient party has specified by prior written notice to the sending party. * * * *
Xxxx Xxxxxxxx X. Give Xxxxx X. Xxxxxx Xxxxxx X. Xxxxxx XXXX PARTNERS LLP 000 Xxxxx Xxxxxx Xxx Xxxx, XX 00000 (000) 000-0000 Attorneys for Plaintiff Supernus Pharmaceuticals, Inc. Of Counsel: Xxxxxx X. Mukerjee Xxxxx X. Xxxxxxxxxx XXXXXX XXXXXX XXXXXXXX LLP 000 Xxxxxxx Xxxxxx Xxx Xxxx, XX 00000-2585 (000) 000-0000 deepro.xxxxxx xx@xxxxxx.xxx xxxxx.xxxxxxxxxx@xxxxxx.xxx Xxxxxxxx Xxxxx Xxxxxx X. Xxxxxx Xxxxxx Xxxxxxxxx XXXXXX XXXXXX XXXXXXXX LLP 000 X. Xxxxx Street, Suite 2900 Charlotte, NC 28202-4213 (000) 000-0000 xxxxx.xxxxx@xxxxxx.xxx xxx.xxxxxx@xxxxxx.xxx xxxxxx.xxxxxxxxx@xxxxxx.xxx Attorneys for Defendants Apotex Inc. and Apotex Corp. SO ORDERED Dated: UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY SUPERNUS PHARMACEUTICALS, INC. Plaintiff, v. APOTEX INC. and APOTEX CORP., Defendants. Civil Action No. 22-cv-322(MAS)(TJB)
Xxxx Xxxxxxxx X. Give Xxxxx X. Xxxxxx Xxxxxx X. Xxxxxx XXXX PARTNERS LLP 000 Xxxxx Xxxxxx Xxx Xxxx, XX 00000 (000) 000-0000 Attorneys for Plaintiff Supernus Pharmaceuticals, Inc. Of Counsel: Xxxxxx X. Mukerjee Xxxxx X. Xxxxxxxxxx XXXXXX XXXXXX XXXXXXXX LLP 000 Xxxxxxx Xxxxxx Xxx Xxxx, XX 00000-2585 (000) 000-0000 xxxxxx.xxxxxxxx@xxxxxx.xxx xxxxx.xxxxxxxxxx@xxxxxx.xxx Xxxxxxxx Xxxxx Xxxxxx X. Xxxxxx Xxxxxx Xxxxxxxxx XXXXXX XXXXXX XXXXXXXX LLP 000 X. Xxxxx Street, Suite 2900 Charlotte, NC 28202-4213 (000) 000-0000 xxxxx.xxxxx@xxxxxx.xxx xxx.xxxxxx@xxxxxx.xxx xxxxxx.xxxxxxxxx@xxxxxx.xxx Attorneys for Defendants Apotex Inc. and Apotex Corp. SO ORDERED Dated: EXHIBIT C [COMPANY LETTERHEAD] [DATE] [NAME] Director Office of Generic Drugs (HFD-600) Center for Drug Evaluation and Research White Oak Building 75; Room [_] 00000 Xxx Xxxxxxxxx Xxxxxx Silver Spring, Maryland 20993-0002 RE: SELECTIVE WAIVER OF EXCLUSIVITY ANDA No. 213369 Oxcarbazepine Extended Release Tablets Dear [NAME]: Reference is made to Supemus Pharmaceuticals Inc.’s (“Supernus”) NDA No. 202810 for oxcarbazepine extended release tablets, 150mg, 300 mg and 600 mg, and any associated pediatric and/or other statutory or regulatory exclusivities listed in the Orange Book in connection with the above-referenced NDA. Reference is also made to the above-referenced ANDA No. 213369 for oxcarbazepine extended release tablets held by Apotex Inc. The purpose of this correspondence is to notify the Agency that Supemus has granted a license to Apotex Inc. and Apotex Corp, (together, “Apotex”) to market its oxcarbazepine extended release tablets. Pursuant to the terms of the license, Supemus also granted to Apotex a selective and limited waiver of any unexpired periods of pediatric and/or other statutory or regulatory exclusivities that might be listed in the Orange Book in connection with NDA No. 202810 with respect to the above-referenced ANDA No. 213369 held by Apotex Inc. for oxcarbazepine extended release tablets. Accordingly, and for the sole purpose of effectuating the license granted by Supernus to Apotex. Supernus hereby selectively waives its right to any unexpired periods of pediatric and/or other statutory or regulatory exclusivities listed in connection with NDA No. 202810, solely to the extent necessary to enable the approval of ANDA No. 213369 for oxcarbazepine extended release tablets. The Agency’s prompt attention to this matter is requested and appreciated. If there are any questions regarding this correspondenc...
Xxxx Xxxxxxxx X. Xxxxxx or to such other address or to the attention of such other person as the recipient party has specified by prior written notice to the sending party.
Xxxx Xxxxxxxx X. XXXXXX Xx. Xxxx (age 52) has served as Vice President and Corporate Xx. Xxxxxx (age 50) is President of Xxxxxx Enterprises, Inc., Secretary of the Company since 1997 and Vice President and a freight agency primarily representing the Landstar Carrier Corporate Secretary of the Association since March 1987 and Group, a full truckload carrier serving 48 states, Mexico, and March 1982, respectively. Canada. Xxxxxx Enterprises, Inc., located in Cincinnati, Ohio, is also a real estate management and development XXXXX X. XXXXX company. He has been a director since 1991. Xx. Xxxxx (age 61) has served as Senior Vice President of GS Financial and Guaranty Savings since December 2005; prior XXXXX X. XXXXX thereto, Xx. Xxxxx served as interim President and Chief Xx. Xxxxx (age 53) is an attorney and has served as Executive Executive Officer of GS Financial and Guaranty Savings from Vice President of GS Financial since February 1997 and January 2005 until December 2005. Xx. Xxxxx previously served Executive Vice President of Guaranty Savings since 1985. Mr. as Vice President of the Company and the Association from Xxxxx also serves as legal counsel and Personnel Manager of February 1997 and 1987, respectively until January 2005. He Guaranty Savings, and performs certain legal services for also serves as a member of both loan committees of Guaranty Guaranty Savings and its borrowers in connection with real Savings and as the company security officer. estate loan closings and receives fees from the borrowers in connection therewith. He has been a director since 1982. J. XXXXXX XXXXX Xx. Xxxxx (age 41) has served as Chief Financial Officer and XXXXXX X. XXXXX Senior Vice President of GS Financial and Guaranty Savings Xx. Xxxxx (age 54) served as President and Chief Executive since January 2006. Prior thereto, Xx. Xxxxx was a Officer of the Company from February 1997 to January 2005, and self-employed consultant providing internal audit, accounting the Association from March 1985 to January 2005. He has been a and loan review services primarily to banks in the greater New director since 1982. Orleans area, including GS Financial and Guaranty Savings since January 2002. Previously, Xx. Xxxxx was employed as an accounting manager at Xxxxxxx Enterprises, Inc., Metairie, Louisiana, from September 2000 through January 2002, and as an audit manager at Xxxxxx Xxxxxxxx LLP from December 1992 to September 2000. GS Financial Corp and Subsidiary --------------------------------------...
Xxxx Xxxxxxxx X. Xxxxx Xxxxxxx X. Xxxx XXXX PARTNERS LLP 000 Xxxxx Xxxxxx Xxx Xxxx, XX 00000 (000) 000-0000 Attorneys for Plaintiff Supernus Pharmaceuticals, Inc. Xxxxxxxx XxXxxxxxx Xxxxxx X. Xxxxxx Xxxxxx Xxxxxxx XXXXXXX XXXXXX & GREEN, P.C. 000 Xxxxxxx Xxxx Xxxx, Xxxxx 000 Xxxxxxxxx, Xxx Xxxxxx 00000 (000) 000-0000 OF COUNSEL: Xxxxxxx X. Xxxxxxxx Xxxxx X. Xxxxxxx Xxxxxxx X. Xxxxxxxx Xxxxx X. Xxxxx XXXXX LORD LLP 000 Xxxxx Xxxxxx Xxxxx Chicago, IL 00000 (000) 000-0000 Attorneys for Defendants Zydus Pharmaceutical (USA) Inc. and Zydus Lifesciences Limited SO ORDERED Dated: __________ __________________________________ THE XXX. XXXXXXXXX XXXXXXX UNITED STATES DISTRICT JUDGE
Xxxx Xxxxxxxx X. XXXXXX ------------------------- ------------------------- Xxxxxxx X. Xxxx Xxxxxxxx X. Xxxxxx
